Novo delays denecimig review as Novo Nordisk stock trades EUR 33.20

Published on 10/07/2026 at 09:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Denecimig review extends beyond the third quarter. Novo Nordisk stock costs EUR 33.20 on October 7, 2026 after EUR 33.22, minus 0.06 percent.

Isometrisches 3D-Diorama Pharma-Reinraum mit Abfüllanlage, Low-Poly-Stil — Novo Nordisk A/S (DK0062498333): isometrisches Low-Poly-Diorama eines pharmazeutischen Reinraums mit steriler Abfüllanlage, Illustration mit AI erstellt.

Novo Nordisk (ISIN DK0062498333) was trading at EUR 33.20 at Lang & Schwarz on October 7, 2026 at 9:36 a.m. CEST, while its denecimig review remained ongoing after a facility-related extension. As Reuters reported on October 2, 2026, the US Food and Drug Administration extended its review of the hemophilia A treatment because manufacturing remediation work is still underway.

Facility work delays the decision

Novo submitted the denecimig application in September 2025 and had expected an FDA decision in the third quarter of 2026. The company now targets a US launch in the first half of 2027, subject to regulatory approval, according to Reuters on October 2, 2026.

The regulatory delay is concentrated in the manufacturing site. Reuters reported on October 2, 2026, that the FDA did not raise concerns about the clinical efficacy or safety data submitted for denecimig, and that the site issue does not affect Novo Nordisk's other marketed medicines.

Sales grew in the second quarter

Novo Nordisk reported adjusted sales of DKK 78.488 billion in the second quarter of 2026, up 7.00 percent at constant exchange rates. Adjusted operating profit reached DKK 33.389 billion, an 11.00 percent increase, according to GlobeNewswire in the company release dated August 4, 2026.

The same release put adjusted sales and adjusted operating profit growth guidance for full-year 2026 at 0.00 percent to minus 6.00 percent at constant exchange rates. That contrast matters for the stock: operating growth in the second quarter remained positive, while the full-year outlook still reflects pressure on the broader business.

Stock holds near the morning level

The next reported results date is November 4, 2026, according to Gekko. For investors, the immediate balance is therefore between a delayed denecimig regulatory decision and the company's quantified second-quarter growth.

EUR 33.20 at Lang and Schwarz

Novo Nordisk stock was trading at EUR 33.20 at Lang & Schwarz on October 7, 2026 at 9:36 a.m. CEST, minus 0.06 percent versus the prior close of EUR 33.22. The further course of trading is shown by the continuously updated real-time quote of Novo Nordisk stock.